56 Results
Sort By:
Published on January 8, 2024
Johnson & Johnson (J&J) announced today it has entered into a definitive agreement to acquire Ambrx Biopharma, a clinical-stage biopharmaceutical company with a proprietary synthetic biology platform, for $2 billion. Ambrx has been advancing its portfolio of next-generation antibody drug conjugates (ADCs) in a range of cancer indications. With the…
Published on July 5, 2023
AstraZeneca’s antibody drug conjugate datopotamab deruxtecan (Dato-DXd) has shown a statistically significant improvement for the dual primary end-point of progression-free survival (PFS) in patients with advanced or metastatic non-small cell lung cancer (NSCLC) compared to the current standard-of-care treatment docetaxel, the company announced on Wednesday. The company also noted that…
Published on January 11, 2023
Ajinomoto has announced a deal with Exelixis to incorporate AJICAP, its proprietary site-specific bioconjugation and linker technologies, in the development of Exelixis antibody-drug conjugate (ADC) programs. Ajinomoto is eligible to receive development, regulatory, and commercial milestone payments as well as royalties on commercial sales. Exelixis is developing next generation ADCs…
Published on August 16, 2022
By Scott Tomlins, MD, PhD, Co-Founder & Chief Medical Officer, Strata Oncology Sponsored content brought to you by ADCs are part of the expression-based therapy revolution in cancer treatment Oncology is seeing accelerated development of new expression-based therapy classes with the potential to deliver unprecedented improvements in patient outcomes.…
Published on November 9, 2020
Tumor size has a strong impact on survival rates of patients with pancreatic cancer (PC), which are some of the worst of all cancer with a five-year survival rate of only 10%. The larger the tumor, the less likely it is to be cured by resection. There have been cases,…
Published on November 8, 2023
Bristol Myers Squibb is acquiring Orum Therapeutics’ ORM-6151 program for $100M upfront and total deal value of $180M. In a twist on antibody-drug conjugates (ADCs), Orum is pioneering Dual-Precision Targeted Protein Degradation (TPD²) and Targeted Protein Stabilization (TPS²). ORM-6151 is a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader that has received the…
Published on October 5, 2023
Synthetic DNA company Twist Bioscience announced today that it has entered an antibody discovery, option and license agreement with pharma giant Bayer valued at up to $188 million. The agreement will see Twist Biopharma Solutions leverage its “Library of Libraries” to conduct antibody research against unnamed therapeutic targets, with Bayer…
Published on April 18, 2023
As part of the annual meeting of the American Association for Cancer Research (AACR) in Orlando, FL, researchers from the Perelman School of Medicine at the University of Pennsylvania have not only identified a new target for drug-resistant ovarian cancer but also provided supporting evidence for a potential treatment approach.…
Published on March 31, 2023
Confo Therapeutics, a leader in targeting G-protein coupled receptors (GPCRs), this week announced an agreement with Daiichi Sankyo for the discovery and development of small molecule agonists against an undisclosed CNS target. Confo will receive upfront and milestone payments totaling $183 million and tiered royalties on sales from any resulting…
Published on January 9, 2023
The biotech company Aethon Therapeutics has launched in New York to develop antibody immunotherapies for tumors that have developed resistance to current cancer drugs. The company is funding its work with a $30 million Series A round. Aethon is the result of an alliance between the life sciences venture capital…
Published on September 21, 2021
Over the last week, the world of cancer research, diagnostics and therapeutics has been congregating on the European Society of Medical Oncology (ESMO) website to view a wide variety of cutting-edge research presentations at the organization’s annual conference. The biggest congress in Europe with a focus on cancer research, the…
Published on August 18, 2021
Triple-negative breast cancer (TNBC) is notoriously difficult to treat because it lacks the receptors for estrogen, progesterone, and the growth factor HER2, all three of which can be targeted with effective cancer therapies. Standard chemotherapy regimens provide limited benefit against TNBC, and patients with metastatic disease have a poor prognosis…
Published on July 17, 2019
A new device rapidly measures the efficacy of targeted cancer drugs. And, that could be a game-changer. The ability to figure out early if targeted drugs are working in individual patients is critical to the attempts to provide precision therapy. A description of the new device appears in the 15…
Published on December 19, 2023
Two new deals around antibody drug conjugates (ADCs) were just struck. Pfizer will develop and commercialize Nona Biosciences’ MSLN-targeted ADC HBM9033 in a deal worth potentially $1B+. Meanwhile, Biocytogen Pharmaceuticals announced an antibody evaluation, option, and license agreement with Ona Therapeutics. The deal includes an option to exclusively license selected…
Published on May 1, 2024
Enlaza Therapeutics yesterday announced a $100 million Series A financing to further develop its proprietary covalent protein technologies and support advancement of its nascent pipeline to the clinic. The company’s aim is to bring covalency to biologic therapies. This approach could be useful in one of today’s most active areas…